| 1848年 |
Charles Pfizer & Company was founded in Brooklyn in 1849 by cousins Charles Pfizer and Charles Erhart, whose first product was an antiparasitic called santonin that treated intestinal worms. They achieved early success by developing citric acid. |
| 1848年 |
Cousins Charles Pfizer and Charles Erhart founded Charles Pfizer & Company in a red brick building in Brooklyn, NY. |
| 1867年 |
Pfizer buys and renovates a post-Revolutionary-era building at 81 Maiden Lane in Manhattan and moves its headquarters there. |
| 1881年 |
Pfizer opens offices and a warehouse in Chicago, Illinois, its first location outside of New York. |
| 1900年 |
Pfizer files an official certificate of incorporation in the state of New Jersey, with authorized capital of $2 million divided into 20,000 shares of $100 each. |
| 1905年 |
Emile Pfizer was the last member of the Pfizer/Erhart family to be actively involved with the company. He was president from 1906 to 1941. |
| 1906年 |
Emile Pfizer, Charles Pfizer's youngest son, is appointed President at a special board meeting. He serves as President from 1906 to 1941 and briefly as Chairman in 1941. |
| 1919年 |
Pfizer chemist James Currie and his assistant, Jasper Kane, successfully pioneer the mass production of citric acid from sugar through mold fermentation—an achievement that eventually frees Pfizer from dependency on European citrus growers. |
| 1924年 |
Charles Pfizer & Co. turns 75 years old. A celebration at the Brooklyn plant, which has 306 employees, marks the milestone. |
| 1929年 |
William H. Erhart, son of Charles Erhart, one of the two original founders. He became vice president of the company in 1900 and served as Chairman of the Board from 1929 to 1940. |
| 1929-01-10 |
On January 10, 1929, John Anderson announces he is stepping down as chairman of the board. William Erhart is named the new chairman, Emile Pfizer continues to serve as president, and John Anderson's son, George, becomes senior vice president. |
| 1936年 |
Doctor Richard Pasternack develops a fermentation-free method for producing ascorbic acid, vitamin C. After building a new plant and initiating a 24-hour-a-day, seven-day-a-week production schedule, Pfizer becomes the world's leading producer of vitamin C. |
| 1938年 |
Pfizer pushes ahead in 1938 with production of vitamin B-2, or riboflavin, and eventually develops a vitamin mix that includes riboflavin, thiamin, niacin, and iron. |
| 1939年 |
Pfizer succeeds so well in the production of citric acid by fermenting sugar that a pound of citric acid, which had cost $1.25 in 1919, tumbles to 20¢, and Pfizer is widely recognized as a leader in fermentation technology. |
| 1941年 |
Pfizer responds to an appeal from the United States Government to expedite the manufacture of penicillin to treat Allied soldiers fighting in World War II. Of the companies pursuing mass production of penicillin, Pfizer alone uses fermentation technology. |
| 1942-06-22 |
Pfizer would remain a privately held company until June 22, 1942, when 240,000 shares of new common stock were offered to the public. |
| 1943-04-17 |
The company's contribution to the war effort is heralded nationwide and earns Pfizer the coveted Army-Navy "E" Award on April 17, 1943. |
| 1944年 |
Pfizer is successful in its efforts to mass-produce penicillin and becomes the world's largest producer of the "miracle drug." |
| 1945年 |
George A. Anderson becomes Pfizer's chairman of the board. John L. Smith fills the office of President. |
| 1950年 |
Terramycin® (oxytetracycline), a broad-spectrum antibiotic that is the result of the Company's first discovery program, becomes the first pharmaceutical sold in the United States under the Pfizer label. Pfizer begins expansion into overseas markets and the International Division is created. |
| 1950-03-15 |
Upon its approval by the United States Food and Drug Administration on March 15, 1950, eight specially trained Pfizer pharmaceutical salesmen waiting for word at pay phones across the nation move into action to get inventory to wholesalers and to educate physicians about Pfizer's first proprietary pharmaceutical product. |
| 1951年 |
In a major international expansion, Pfizer operations are established in Belgium, Brazil, Canada, Cuba, England, Mexico, Panama, and Puerto Rico. John "Jack" Powers, Jr., then assistant to Pfizer President John McKeen, directs his international teams to “study the economy, establish proper contacts with government officials, learn the language, history, and customs, and hire local employees wherever possible.” |
| 1952年 |
Pfizer establishes an Agricultural Division dedicated to offering cutting-edge solutions to animal health problems. The division opens its 700-acre farm and research facility in Terre Haute, Indiana. |
| 1953年 |
After its acquisition, J.B. Roerig and Company, specialists in nutritional supplements, becomes a division of Pfizer. Roerig remains an integral part of Pfizer's outstanding marketing division. |
| 1955年 |
A fermentation plant opens in England, laying the foundation for Pfizer's research and development operations in Great Britain. Pfizer partners with Japan's Taito to manufacture and distribute antibiotics. |
| 1958年 |
New Pfizer pharmaceutical plants begin production in Mexico, Italy, and Turkey. International personnel increases from 4,300 in 1957 to over 7,000. |
| 1960年 |
The Company signals its increasing commitment to research by consolidating its medical research laboratory operations in Groton, Connecticut. |
| 1965年 |
Pfizer begins a decade of substantial growth and establishes new World Headquarters in midtown Manhattan. |
| 1966年 |
John J. Powers, Jr. President and Chief Executive Officer Chas. Pfizer & Co., Inc. |
| 1967年 |
Vibramycin® (doxycycline hyclate), the company's first once-a-day broad-spectrum antibiotic is introduced and quickly becomes a top seller. |
| 1968年 |
John J. Powers, Jr.,is named president and CEO. John McKeen, whom he succeeds, remains chairman of the board, a position he holds until 1968, when Powers assumes full leadership of the company. |
| 1971年 |
Pfizer acquires Mack Illertissen, a prosperous manufacturer of pharmaceutical, chemical, and consumer products oriented to the needs of the German marketplace.The Central Research Division is established, combining pharmaceutical, agricultural, and chemical R&D worldwide. It eventually grows to include research centers on three continents. In an era of unprecedented advances in medical discovery, Pfizer makes a long-term investment in research that will pay off years later. |
| 1972年 |
Pfizer crosses the billion-dollar sales threshold. John Powers, Jr., steps down; Edmund T. Pratt, Jr., becomes CEO; and Gerald D. Laubauch becomes President. |
| 1972年 |
Recognizing that the key to Pfizer's future growth lies in its ability to discover and develop innovative pharmaceuticals, Chairman Ed Pratt increases the company's Research and Development budget from about 5 percent to 15 to 20 percent of sales. He also leads the ongoing battle for intellectual property protection worldwide to encourage and safeguard innovation. As a result of his pioneering efforts, Pratt is named as chairman of the President´s Advisory Committee for Trade Negotiations during both the Carter and Reagan administrations. Pfizer establishes a microbiology laboratory for soil screening in Nagano, Japan. The site is expanded in 1985 into a major discovery laboratory complex where researchers are part of worldwide teams seeking novel ways to circumvent the inflammation process in diseases like arthritis and asthma, and new non-addictive analgesics to manage pain. |
| 1976年 |
Pfizer introduces Minipress® (prazosin HCI) in the United States, for the control of high blood pressure. |
| 1978年 |
Mr. Read began his career with Pfizer as an operational auditor. |
| 1980年 |
Feldene® (piroxicam) becomes one of the largest-selling prescription anti-inflammatory medications in the world and, ultimately, Pfizer's first product to reach a total of a billion United States dollars in sales. |
| 1984年 |
Glucotrol® (glipizide), for diabetes, is launched. |
| 1986年 |
The Agricultural Division is renamed the Animal Health Division. |
| 1989年 |
Pfizer launches Procardia® XL (nifedipine) extended-release tablets, an innovative once-a-day medication for angina and hypertension. |
| 1990年 |
William C. Steere, Jr., is appointed President. A year later, he is also named Chief Executive Officer. |
| 1992年 |
William C. Steere, Jr. becomes Chairman of the Board. His goal is to refocus the Company on its core competencies. |
| 1992年 |
Pfizer has a triple rollout of major new medicines: Zoloft® (sertraline hydrochloride) for treatment of depression, Norvasc® (amlodipine besylate) for control of angina and hypertension, and Zithromax® (azithromycin) for respiratory and skin infections. |
| 1993年 |
Pfizer's Sharing the Care, the industry's premier drug-donation program, is launched. Sharing the Care provides medicines to more than one million eligible low-income and uninsured patients throughout the United States. |
| 1994年 |
Originally approved for systemic fungal infections, in 1994 it receives a new indication in the U.S. for vaginal candidiasis. |
| 1995年 |
The Animal Health Division purchases SmithKline Beecham's animal health business, making Pfizer a world leader in the development and production of pharmaceuticals for livestock and companion animals. |
| 1995年 |
Pfizer increases its presence in the Far East by building a pharmaceutical plant in Dalian, China and expanding throughout growing markets in the Pacific Rim. Cardura® (doxazosin mesylate) is introduced in the United States for the treatment of benign prostate hyperplasia (BPH). |
| 1997年 |
Fortune® magazine names Pfizer the world's most admired pharmaceutical company. |
| 1998年 |
Pfizer's roster of outstanding drugs grows with the launch of Viagra® (sildenafil citrate), a breakthrough treatment for erectile dysfunction. |
| 1998年 |
Pfizer invests more than $3.3 billion in research and development. |
| 1999年 |
Pfizer celebrates its 150th anniversary as one of the world's premier pharmaceutical companies. Recognized for its success in discovering and developing innovative drugs for human discovery, Forbes® magazine names Pfizer "Company of the Year." Pfizer takes the drug discovery process to a new level of efficiency with the opening of the Discovery Technology Center in Cambridge, Massachusetts. |
| 1999年 |
Utilizing the emerging knowledge of gene families, the Center's mission is to evolve new, more efficient models for discovering drug candidates. These candidates have an increased potential to survive the rigors of drug development. Pfizer investment in research and development exceeds $4 billion for the first time. Learn more about Pfizer's commitment to research. |
| 2000年 |
The Best Get Better—Pfizer and Warner-Lambert merge to form the new Pfizer, creating the world's fastest-growing major pharmaceutical company. |
| 2000年 |
Pfizer and the Ministry of Health of South Africa sign a Memorandum of Understanding to establish the Diflucan® Partnership Program. |
| 2000年 |
Pfizer opens the largest building in the world dedicated to the discovery of new medicines for human and animal health on its Groton, Connecticut research campus. |
| 2001-01-01 |
William C. Steere, Jr. announces his retirement as CEO on January 1, 2001, and steps down as Chairman of the Board in April, following the company's annual meeting. Henry A. McKinnell, Jr., Ph.D. succeeds William C. Steere, Jr. as Chairman and Chief Executive Officer. |
| 2001年 |
Pfizer launches Geodon® (ziprasidone hydrochloride), a new antipsychotic for the treatment of schizophrenia. |
| 2001年06月 |
In June 2001, Hank McKinnell announces a new mission for Pfizer—to become the world's most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live. In July, he announces a commitment to fund the building of a regional treatment and training center on the campus of Makerere University in Kampala, Uganda as part of the Academic Alliance for AIDS Care and Prevention. |
| 2003年 |
Pfizer invests more than $7.1 billion in research and development. |
| 2003年 |
Pfizer launches Relpax® (eletriptan HBr), a medication developed specifically for the treatment of migraines. Pfizer´s Sharing the Care drug-donation program celebrates its 10th anniversary. |
| 2003年 |
Hank McKinnell, CEO and Chairman of Pfizer, announces the Global Health Fellows program at the World AIDS Conference in Barcelona - a call to action for Pfizer colleagues to volunteer in developing countries for up to six months on HIV/AIDS projects. In 2003, the first eighteen Global Health Fellows are sent into the field. |
| 2003-04-16 |
On April 16, 2003 Pfizer Inc and Pharmacia Corporation combine operations, bringing together two of the world´s fastest-growing and most innovative companies. |
| 2004年 |
Pfizer Inc is selected by Dow Jones and Co. to be included in the Dow Jones Industrial Average, which is the best-known stock market barometer in the world. |
| 2004年 |
Caduet® (amlodipine besylate and atorvastatin calcium), the first single pill that treats both high blood pressure and high cholesterol, is launched. |
| 2005年 |
Pfizer launches Lyrica® (pregabalin), the first treatment approved by the U.S. Food and Drug Administration to treat two distinct forms of neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN) and adjunctive treatment of partial onset seizures in adults with epilepsy. |
| 2006年 |
Pfizer's roster of outstanding drugs grows with the launch of Sutent® (sunitinib malate), a new, oral, multikinase inhibitor to treat patients with metastatic renal cell carcinoma (mRCC), or advanced kidney cancer, and gastrointestinal stromal tumor (GIST) after disease progression on, or intolerance to, imatinib mesylate. |
| 2006年 |
Pfizer launches Eraxis™ (anidulafungin), a new medicine to treat certain infections caused by Candida, a yeast-like fungus that can cause serious infections in hospitalized patients or patients with compromised immune systems. |
| 2006年 |
Chantix™ (varenicline), a prescription medicine to help adults stop smoking, is launched by Pfizer. |
| 2006年07月 |
In July 2006, the Pfizer Board of Directors names Jeffrey B. Kindler Chief Executive Officer. Kindler succeeds Hank McKinnell, who will remain Chairman of the Board until his retirement in February, 2007. |
| 2007年 |
Pfizer launches Selzentry™ (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years. Selzentry blocks viral entry into white blood cells, significantly reducing viral load and increasing T-cell counts in treatment-experienced patients infected with a specific type of HIV. |
| 2007年 |
Pfizer launches an online site to provide up-to-date, user-friendly information on the status of its U.S. post-marketing commitments - studies conducted after a medicine receives regulatory approval and designed to provide additional information about the medicine's safety, efficacy or optimal use. This initiative is the first of its kind for a pharmaceutical company. |
| 2008年 |
Jeff Kindler, Chairman and CEO of Pfizer, announces the next step in the company's evolution and outlines the company's plan to establish smaller operating units designed to enhance innovation and accountability, while drawing upon the advantages of Pfizer's scale and resources. These customer-focused business units allow Pfizer to better anticipate and respond to customers' and patients' needs, as well responds to changes in the marketplace. |
| 2008年 |
Pfizer launches a new Medicine Safety Website to help healthcare professionals and patients make better informed decisions about treatment options. |
| 2008年 |
Grameen Health, an affiliate of Grameen Bank, the pioneering micro-financing organization in Bangladesh that shared the Nobel Peace Prize in 2006 for its work to alleviate poverty, partners with Pfizer to identify sustainable models for healthcare delivery in the developing world. |
| 2008年 |
Pfizer launches its Global Regenerative Medicine Unit. The unit is dedicated to understanding the biology of stem cells and the opportunity these cells provide, to discover and develop a new generation of regenerative medicines that may prevent disability, repair failing organs and treat degenerative diseases. |
| 2008年 |
Pfizer enters into an agreement with Medivation to develop and commercialize an investigational medicine, Dimebon, for treating Alzheimer's disease and Huntington's disease. |
| 2009年 |
Pfizer takes a new and unique approach to biomedical research, a move intended bring more innovative medicines to more patients more quickly. Specifically, Pfizer creates two distinct research organizations: The PharmaTherapeutics Research & Development Group, which focuses on discovery of small molecules and related modalities; and The BioTherapeutics Research & Development Group, which focuses on large-molecule research, including vaccines. |
| 2009年 |
Pfizer launches Toviaz (fesoterodine fumarate), a prescription medicine used in adults to treat symptoms of a condition called overactive bladder. |
| 2009年 |
Pfizer enters into major licensing agreements with two Indian-based pharmaceutical companies — Claris Lifesciences Ltd. and Aurobindo Pharma Ltd. |
| 2009年 |
As part of the acquisition of Wyeth in 2009, Pfizer initially implemented a two-division structure for research and development (BioTherapeutics and PharmaTherapeutics) to ensure the progress and steady integration of both legacy organizations. |
| 2009-10-15 |
On October 15, 2009, Pfizer acquires Wyeth, creating a company with a broad range of products and therapies that touch the lives of patients and consumers every day and at every stage of life. |
| 2010年 |
Ian Read joins Pfizer as Chief Executive Officer. |
| 2010年 |
Pfizer announces a diversified R&D platform named Pfizer Worldwide Research and Development, supporting excellence in small molecules, large molecules and vaccine research and development. |
| 2011年 |
Pfizer Completes Sale of Capsugel Business to KKR. |
| 2012年 |
Pfizer's subsidiary, Zoetis™ Inc, files IPO registration statement |
| 2013年 |
Pfizer's subsidiary, Zoetis™ Inc., files a registration statement with the U.S. Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. The offering is expected to represent an ownership stake of up to 20 percent. Prior to completion of the offering, which is targeted for the first half of 2013, Pfizer will transfer its animal health business to Zoetis. |
| 2013年 |
Pfizer announces plans to move forward to internally separate its commercial operations into three business segments, two of which will include Innovative business lines and a third which will include the Value business line. Each of the three segments will include developed markets and emerging markets. |
| 2014年 |
Pfizer announces that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. |
| 2014年01月 |
The changes are implemented in January 2014 in countries that do not require a consultation with works councils or unions, and are then implemented in countries that require consultation after the successful conclusion of those processes. |
| 2015年 |
Pfizer announces that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira. This strategically complementary combination adds a growing revenue stream and a platform for growth for Pfizer’s GEP business. |
| 2017年 |
Pfizer and Corning Incorporated announce collaborations that have enabled the modernization of pharmaceutical packaging with the introduction of Corning Valor™ Glass. This revolutionary pharmaceutical glass packaging solution enhances the storage and delivery of today’s drug formulations and provides more reliable access to medicines essential to public health. |
| 2020年 |
Pfizer leads the world in developing a vaccine and treatment in response to the COVID-19 pandemic and commits to lightspeed manufacturing to expand vaccine and treatment access to people around the world. |
| 2022年 |
Pfizer acquires several companies: |
| 2022年 |
Pfizer launches ‘An Accord for a Healthier World,’ a groundbreaking initiative that aims to provide all of Pfizer’s patented, high-quality medicines and vaccines available in the U.S. or the European Union on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. The Accord seeks to greatly reduce the health inequities that exist between many lower-income countries and the rest of the world. |
| 2022年 |
Ian Read joins Pfizer as Chief Executive Officer. Prior to this, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units—Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. |
| 2023年 |
Pfizer announces the acquisition of Seagen Inc., a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. |
| 2024年 |
Pfizer celebrates 175 years of making breakthroughs that change people’s lives. |
| 2025年 |
Pfizer announces a historic agreement with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening America’s role as the global leader in biopharmaceutical innovation. |
| 2025年 |
Pfizer announces the successful completion of its acquisition of Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. |
